By Connor Hart
Weight-loss drug stocks slid after the Centers for Medicare & Medicaid Services said it wouldn't finalize a provision set to provide coverage for anti-obesity medications. The agency added it may address the provision--which would have expanded coverage to about 3.4 million Medicare beneficiaries who have obesity not combined with a condition for which these medications are already covered--in future rulemaking as appropriate. Shares of Eli Lilly fall 2.9%, to $717.02, in after-hours trading. American depository receipts of Novo Nordisk slide 1.4%, to $61.68, and shares of Hims & Hers edge 1.2% lower, to $25.68.
Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade barriers. The solar-technology company added it is also identifying additional domestic component vendors to support its diversified manufacturing operations. Shares climb 3.2%, to $2.89, in post-market trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 04, 2025 18:23 ET (22:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。